Doxorubicin (DOX) is widely used as an effective chemotherapy agent in cancer treatment. Cardiac toxicity in cancer treatment with DOX
Abstract
Doxorubicin (DOX) is widely used as an effective chemotherapy agent in cancer treatment. Cardiac toxicity in cancer treatment with DOX demand urgent attention and no effective treatment has been established for DOX-induced cardiomyopathy. It has been well documented that human amniotic membrane proteins (AMPs), extracted from amnion membrane (AM), have antioxidant, anti-apoptotic, and cytoprotective properties. Therefore, in this study, we aimed to investigate the protective effects of AMPs against cardiotoxicity induced by DOX in cultured rat cardiomyocyte cells (H9c2). DOX-induced cell injury was evaluated using multi-parametric assay including thiazolyl blue tetrazolium bromide (MTT), the release of lactic dehydrogenase (LDH), intracellular Ca2+ , reactive oxygen species (ROS) levels, cellular antioxidant status, mitochondrial membrane potential (ΔΨm), malondialdehyde (MDA), and NF-κB p65 DNA-binding activity. Moreover, expression profiling of apoptosis-related genes (P53, Bcl-2, and Bax) and Annexin V by flow cytometry were used for cell apoptosis detection. It was shown that AMPs pretreatment inhibited the cell toxicity induced by DOX. AMPs effectively attenuated the increased levels of LDH, Ca2+ , ROS, and MDA and also simultaneously elevated the ΔΨm and antioxidant status such as superoxide dismutase (SOD) and Catalase (CAT) in pretreated H9c2 cardiomyocytes. Besides, the activity of NF-kB p65 was reduced and the p53 and Bax protein levels were inhibited in these myocardial cells subjected to DOX. These findings provide the first evidence that AMPs potently suppressed DOX-induced toxicity in cardiomyocytes through inhibition of oxidative stress and apoptosis. Thus, AMPs can be a potential therapeutic agent against DOX cardiotoxicity.
PMID: 32086724 [PubMed - as supplied by publisher]
12:35
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
12:35
In reply to this message
pubmed: ctoall&ca or conall
Trastuzumab related cardiotoxicity in nonmetastatic breast cancer: A real-world scenario.
Trastuzumab related cardiotoxicity in nonmetastatic breast cancer: A real-world scenario.
Ann Oncol. 2019 May;30 Suppl 3:iii69
Authors: Shrivastva S, Prasad SK, Chennamaneni R, Stalin B, Konatam ML, Gundeti S
PMID: 32084902 [PubMed - as supplied by publisher]
12:35
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
12:35
In reply to this message
pubmed: ctoall&ca or conall
Anti HER-2 therapies and left ventricular dysfunction: A prospective study.
Anti HER-2 therapies and left ventricular dysfunction: A prospective study.
Ann Oncol. 2019 May;30 Suppl 3:iii32
Authors: Daniele AJ, Gregorietti VE
PMID: 32084781 [PubMed - as supplied by publisher]
15:14
Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
15:14
In reply to this message
pubmed: caandvteortroorpul
A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.
Related Articles
A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer.
Lung Cancer. 2020 Jan 22;142:34-40
Authors: Alexander M, Pavlakis N, John T, O'Connell R, Kao S, Hughes BGM, Lee A, Hayes SA, Howell VM, Clarke SJ, Millward M, Burbury K, Solomon B, Itchins M
Comments
Post a Comment
اكتب تعليق حول الموضوع